In a recent interview about President Biden’s recent executive order on artificial intelligence (AI), Morris Panner, the president of Intelerad Medical Systems, shared his concerns that the executive order, while well-intentioned, may wind up stifling innovation and the continued evolution of AI in radiology.
While President Biden’s recently issued executive order on artificial intelligence (AI) emphasizes new standards for the development and use of AI models, Morris Panner has a few reservations and suggests that the executive order may turn out to be “HIPAA for AI” in some respects.
“As well intentioned as HIPAA (Health Insurance Portability and Accountability Act) was, it really shut off a generation of innovation in health care because of what it did to information flow and risk taking in innovation around data,” claimed Panner, the president of Intelerad Medical Systems, in a recent interview.
“I understand why we have HIPAA. We respect HIPAA. We care a lot about patient privacy. But HIPAA was and has continued to be something that most people don’t think really has lived up to its reputation as a portability act. In many ways, the executive order takes some legitimate problems and tries to address them but ends up doing it in a way that will stifle innovation and make it harder for us to take risks at the beginning of the AI innovation cycle.”
(For related content, see “How Will President Biden’s New Executive Order on AI Impact Radiology?,” “Can AI Improve Triage Efficiency in Radiology Workflows for Follow-Up X-Rays?” and “FDA Clears Emerging AI-Enabled Teleradiology Platform.”)
While the executive order references the bolstering of access to technical resources and assistance for smaller companies seeking to develop AI models, Panner suggests the executive order may lead to “a lot of registration and government examination” that would thwart smaller innovative companies and favor more established companies with larger regulatory capabilities but who are also more risk adverse.
For more insights from Morris Panner, watch the video below.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.